Table 1 Characteristics of the study subjects
|  | Survivor group (n = 256) | Nonsurvivor group (n = 50) | p |
|---|---|---|---|
Age (years) | 64.7 ± 15.2 | 75.3 ± 10.7 | <0.01 |
Male (n, %) | 175 (68.4) | 34 (68.0) | NS |
Body mass index (kg/m2) | 24.2 ± 4.5 | 22.1 ± 3.8 | <0.01 |
Systolic blood pressure (mmHg) | 134 ± 27 | 124 ± 32 | 0.03 |
Diastolic blood pressure (mmHg) | 78 ± 19 | 70 ± 18 | <0.01 |
Heart rate (/min) | 85 ± 30 | 82 ± 25 | NS |
Ejection fraction (%) | 51.6 ± 16.7 | 39.7 ± 20.1 | <0.01 |
Diabetes mellitus (n, %) | 86 (33.6) | 21 (42.0) | NS |
Dyslipidemia (n, %) | 191 (74.6) | 28 (56.0) | 0.01 |
Hypertension (n, %) | 174 (68.0) | 34 (68.0%) | NS |
Atrial fibrillation (n, %) | 59 (23.1) | 22 (44.0) | <0.01 |
Ischemic heart disease (n, %) | 141 (55.1) | 27 (54.0) | NS |
Diagnosis | |||
 Acute decompensated heart failure (n, %) | 71 (27.7) | 34 (68.0) | <0.01 |
 Acute coronary syndrome (n, %) | 121 (47.3) | 8 (16.0) | <0.01 |
Laboratory data | |||
 Total cholesterol (mg/dL) | 172 ± 38 | 153 ± 27 | <0.01 |
 LDL-cholesterol (mg/dL) | 105 ± 31 | 93 ± 21 | 0.03 |
 HDL- cholesterol (mg/dL) | 44 ± 14 | 42 ± 12 | NS |
 Triglycerides (mg/dL) | 116 ± 72 | 86 ± 39 | 0.01 |
 eGFR (mL/min/1.73m2) | 71.9 ± 27.4 | 45.4 ± 26.8 | <0.01 |
 Hemoglobin A1c (%) | 6.2 ± 1.2 | 6.1 ± 0.8 | NS |
 Total protein (g/dL) | 6.6 ± 0.6 | 6.5 ± 0.6 | NS |
 Albumin (g/dL) | 3.8 ± 0.6 | 3.4 ± 0.5 | <0.01 |
 Brain natriuretic peptide (pg/mL) | 490 ± 762 | 1443 ± 1357 | <0.01 |
Medication | |||
 Diuretics (n, %) | 45 (17.7) | 29 (59.2) | <0.01 |
 Antiplatelets (n, %) | 95 (37.4) | 25 (51.0) | NS |
 Anticoagulants (n, %) | 39 (15.4) | 22 (44.9) | <0.01 |
 ACE-I/ARBs (n, %) | 111 (43.7) | 29 (59.2) | NS |
 β-blockers (n, %) | 82 (32.3) | 22 (44.9) | NS |
 Calcium channel blockers (n, %) | 94 (37.0) | 18 (36.7) | NS |
 Inotropic agents (n, %) | 3 (1.2) | 9 (18.4) | <0.01 |
 Statins (n, %) | 81 (31.9) | 16 (32.7) | NS |
 Oral hypoglycemic agents (n, %) | 45 (17.7) | 9 (18.4) | NS |
 Insulin (n, %) | 15 (5.9) | 3 (6.1) | NS |